Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pevonedistat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAE1 known ✓ | Q13564 | 18/20 | 1.00 |
| ▸ | UBA3 known ✓ | Q8TBC4 | 16/20 | 1.00 |
| ▸ | UBA6 | A0AVT1 | 3/20 | 1.00 |
| ▸ | SAE1 | Q9UBE0 | 3/20 | 1.00 |
| ▸ | CA2 | P00918 | 2/20 | 1.00 |
| ▸ | GRK5 | P34947 | 1/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 1.00 |
| ▸ | NEDD8 | Q15843 | 1/20 | 1.00 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 1.00 |
| ▸ | ATG7 | O95352 | 1/20 | 0.58 |
| ▸ | UBA7 | P41226 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pevonedistat SCHEMBL14321349 | 1.00 | NAE1 (1.00) | NAE1UBA3UBA6SAE1CA2 | |
| Pevonedistat SCHEMBL10048256 | 1.00 | NAE1 (1.00) | NAE1UBA3UBA6SAE1CA2 | |
| Pevonedistat SCHEMBL14328898 | 1.00 | NAE1 (1.00) | NAE1UBA3UBA6SAE1CA2 | |
| Pevonedistat SCHEMBL23924438 | 1.00 | NAE1 (1.00) | NAE1UBA3UBA6SAE1CA2 | |
| Pevonedistat SCHEMBL15685348 | 1.00 | NAE1 (1.00) | NAE1UBA3UBA6SAE1CA2 | |
| Pevonedistat SCHEMBL23833815 | 1.00 | NAE1 (1.00) | NAE1UBA3UBA6SAE1CA2 | |
| Pevonedistat SCHEMBL1800436 | 1.00 | NAE1 (1.00) | NAE1UBA3UBA6SAE1CA2 | |
| Pevonedistat SCHEMBL20603286 | 1.00 | NAE1 (1.00) | NAE1UBA3UBA6SAE1CA2 | |
| Pevonedistat SCHEMBL22472958 | 1.00 | NAE1 (1.00) | NAE1UBA3UBA6SAE1CA2 | |
| Pevonedistat SCHEMBL192291 | 1.00 | NAE1 (1.00) | NAE1UBA3UBA6SAE1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963456-B2 | Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD (JP) | 2018-05-08 | — | — | US | disclosed |
| US-9963456-B2 | Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD (JP) | 2018-05-08 | — | — | US | disclosed |
| EP-3103802-B1 | NOVEL PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME, ESPECIALLY AGENT FOR PREVENTION AND/OR TREATMENT OF TUMORS ETC BASED ON NAE INHIBITORY EFFECT | TAIHO PHARMACEUTICAL CO LTD (JP) | 2017-11-08 | — | — | EP | disclosed |
| WO-2017111074-A1 | ANTITUMOR EFFECT POTENTIATOR COMPRISING PYRROLOPYRIMIDINE COMPOUND | 大鵬薬品工業株式会社 | 2017-06-29 | — | — | WO | disclosed |
| US-20170066772-A1 | NOVEL PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME, ESPECIALLY AGENT FOR PREVENTION AND/OR TREATMENT OF TUMORS ETC BASED ON NAE INHIBITORY EFFECT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
| US-20150366886-A1 | ADMINISTRATION OF NEDD8-ACTIVATING ENZYME INHIBITOR AND HYPOMETHYLATING AGENT | MILLENNIUM PHARM INC (US) | 2015-12-24 | — | — | US | disclosed |
| US-8980850-B2 | Administration of a NEDD8-activating enzyme inhibitor and hypomethylating agent | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140249167-A1 | Administration of NEDD8-Activating Enzyme Inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140249167-A1 | Administration of NEDD8-Activating Enzyme Inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-09-04 | — | — | US | disclosed |
| US-20130116208-A1 | ADMINISTRATION OF A NEDD8-ACTIVATING ENZYME INHIBITOR AND HYPOMETHYLATING AGENT | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20120115892-A1 | ADMINISTRATION OF NEDD8-ACTIVATING ENZYME INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116208-A1 | ADMINISTRATION OF A NEDD8-ACTIVATING ENZYME INHIBITOR AND HYPOMETHYLATING AGENT | NEDD8, NAE1, UBE2M | NAE1 2/4885UBA3 4/4885UBA6 174/4885 |
| US-20120115892-A1 | ADMINISTRATION OF NEDD8-ACTIVATING ENZYME INHIBITOR | NEDD8, NAE1, CAND1 | NAE1 2/4885UBA3 4/4885UBA6 147/4885 |
| US-20140249167-A1 | Administration of NEDD8-Activating Enzyme Inhibitor | NEDD8, NAE1, CAND1 | NAE1 2/4885UBA3 4/4885UBA6 147/4885 |
| US-20170066772-A1 | NOVEL PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME, ESPECIALLY AGENT FOR PREVENTION AND/OR TREATMENT OF TUMORS ETC BASED ON NAE INHIBITORY EFFECT | WASHC5, NME1, NHERF1 | NAE1 55/4885UBA3 3061/4885UBA6 4510/4885 |
| US-20150366886-A1 | ADMINISTRATION OF NEDD8-ACTIVATING ENZYME INHIBITOR AND HYPOMETHYLATING AGENT | NEDD8, NAE1, UBE2M | NAE1 2/4885UBA3 4/4885UBA6 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.